Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Aditya Sarawgi

UNBELIEVABLE: Is biogen stock outperforming the dow - The Untold Story

Cambridge, Massachusetts-based Biogen Inc. (BIIB) operates as a leading biotech firm, pioneering innovative science to deliver new medicines to transform patients’ lives and to create value for shareholders and communities. Valued at $26.6 billion by market cap, it has a deep understanding of human biology and leverages different modalities to advance first-in-class treatments or therapies that deliver superior outcomes.

Companies worth $10 billion or more are generally described as "large-cap stocks." Biogen fits right into that category, with its market cap exceeding this threshold, reflecting its substantial size, influence, and dominance in the biotech industry.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.